Amgen is building a new Science and Innovation Center in Hyderabad’s Genome Valley, the American biotechnology company announced in August 2026. Scientists at the site will work on discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. Work is due to begin in 2027.
Amgen, headquartered in Thousand Oaks, California, is one of the world’s largest independent biotechnology companies, developing medicines for cardiovascular disease, cancer, inflammation and other serious illnesses. Its global research organisation runs seven laboratories in the United States and abroad, and the company has recently been investing in new science facilities at home, including a $600 million centre at its Thousand Oaks headquarters and a $125 million expansion in South San Francisco.
What the centre will do
The Genome Valley site will join Amgen’s global research network rather than serve as a back office. Its teams will combine laboratory science with data and digital tools, an approach Amgen’s head of research and development, AI and data, Jay Bradner, has framed as central to how the company now discovers drugs. Discovery chemistry covers the design of new molecules, drug metabolism work looks at how the body absorbs and clears them, and precision medicine aims to match treatments to the right patients. Amgen has not disclosed the investment or planned headcount.
Why Hyderabad
Genome Valley is one of India’s oldest life sciences clusters, home to vaccine makers and research operations of global drugmakers such as Eli Lilly and Novartis. Amgen already has a large technology base in the city, which gives it an established talent pipeline and working ties with the Telangana government. IT and Industries Minister D Sridhar Babu welcomed the new centre. Our page on GCCs in Hyderabad follows the city’s growing life sciences cluster.
Amgen’s India footprint
Amgen opened a technology and innovation site of about 524,000 sq ft in Hyderabad’s HITEC City in February 2025, committing $200 million to it through that year with more investment to follow. That centre builds AI and data science capability to support Amgen’s medicine pipeline and its digital work worldwide. The Genome Valley lab will complement it. Naveen Gullapalli is managing director of Amgen India, and Som Chattopadhyay, senior vice president of global business solutions, serves as Amgen’s national executive for the country.
What it signals
Most pharmaceutical capability centres in India started with technology, data and business services. Amgen’s decision to add wet laboratory research in discovery chemistry marks a step into core science. It suggests global drugmakers are growing more willing to place early stage research in India, and it strengthens Hyderabad’s case as the country’s leading life sciences hub.
At a glance
- Home country: United States
- Sector: Healthcare and Life Sciences
- City: Hyderabad
- Date: August 2026
- Status: Expansion of an existing centre
- Scale: New research site in Genome Valley, due to start work in 2027
Follow every new global capability centre in India on our India GCC Tracker.
